{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343525","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-08-11T12:30:17+00:00","discovered_at":"2026-08-11T12:35:02.310845+00:00","generated_at":"2026-08-11T12:35:34.216400+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ultragenyx settles DOJOLVI patent litigation; Esjay generic entry set for 2033","bullets":["Settlement with Esjay resolves ANDA patent suit over DOJOLVI (triheptanoin) in NJ district court.","Esjay gets non-exclusive royalty-free license to market generic DOJOLVI starting Jan 1, 2033, or Jul 1, 2033 if pediatric exclusivity granted.","Other DOJOLVI ANDA patent suits against other filers remain pending in same court.","Settlement to be submitted to FTC and DOJ as required by law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343525","json":"https://secwatch.observer/filing/0001193125-26-343525.json","markdown":"https://secwatch.observer/filing/0001193125-26-343525.md","text":"https://secwatch.observer/filing/0001193125-26-343525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/0001193125-26-343525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526343525/rare-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:35:34.216400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}